Hinge Health

HNGE

Market cap $3.66B

The average of price targets set by Wall Street analysts indicates a potential upside of 29.6% in Hinge Health Inc. (HNGE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

SAN FRANCISCO--(BUSINESS WIRE)--Hinge Health, Inc. (NYSE: HNGE) today announced a new study showing that participants in its chronic back pain program had substantially fewer imaging visits, such as X-rays and MRIs, compared to a similar group of individuals who sought traditional PT care. The peer-reviewed study, published in The Journal of Health Economics and Outcomes Research found that of the 4,330 participants, those who used Hinge Health had 60% fewer imaging visits for low back pain at.

SAN FRANCISCO--(BUSINESS WIRE)--Hinge Health, Inc. (NYSE: HNGE) today announced that its board of directors has authorized a $250 million share repurchase program. “During the first three quarters of 2025, we generated $108 million in cash from operations and $118 million in free cash flow1, reflecting the strength and scalability of our business model,” said James Budge, CFO, Hinge Health. “We maintain a robust balance sheet, with nearly $500 million in cash and investments as of the end of Q3.

Hinge Health, Inc. ( HNGE ) Q3 2025 Earnings Call November 4, 2025 4:30 PM EST Company Participants Bianca Buck Daniel Perez - Co-Founder, CEO & Director James Pursley - President James Budge - Chief Financial Officer Conference Call Participants Rishi Jaluria - RBC Capital Markets, Research Division Jessica Tassan - Piper Sandler & Co., Research Division Saket Kalia - Barclays Bank PLC, Research Division Jailendra Singh - Truist Securities, Inc., Research Division Scott Schoenhaus - KeyBanc Capital Markets Inc., Research Division David Grossman - Stifel, Nicolaus & Company, Incorporated, Research Division Bradley Sills - BofA Securities, Research Division Elizabeth Anderson - Evercore ISI Institutional Equities, Research Division Craig Hettenbach - Morgan Stanley, Research Division Brian Peterson - Raymond James & Associates, Inc., Research Division Richard Close - Canaccord Genuity Corp., Research Division Scott Berg - Needham & Company, LLC, Research Division Presentation Operator Ladies and gentlemen, thank you for joining us, and welcome to the Hinge Health Third Quarter 2025 Earnings Call. [Operator Instructions] I will now hand the conference over to Bianca Buck, Head of Investor Relations.

Hinge Health CEO Daniel Perez talks quarterly results as stock sinks 5%.

SAN FRANCISCO--(BUSINESS WIRE)--Hinge Health, Inc. (NYSE: HNGE) today announced financial results for the third quarter ended September 30, 2025. “With healthcare costs rising dramatically, our mission to automate care delivery has never been more urgent,” said Daniel Perez, Co-Founder and CEO, Hinge Health. “This quarter we surpassed 1.5 million lifetime members, delivered year-over-year revenue growth of 53%, and generated record free cash flow. Our AI-powered platform is transforming care at.

SAN FRANCISCO--(BUSINESS WIRE)--Hinge Health, Inc. (NYSE:HNGE) today announced two AI-powered care tools: Movement Analysis uses computer vision to set a new standard for tracking musculoskeletal (MSK) outcomes, and Robin is an AI Care Assistant that provides instant support for members. Hinge Health also published its AI care principles, which guide the development of AI across its platform. “Our thoughtful investments in AI are transforming how our members experience care,” said Daniel Perez,.

This telehealth company offers customized physical therapy sessions through a phone app.

Hinge Health demonstrates robust revenue growth, an expanding client base, and strong cash flow, positioning it well for organic pipeline funding. HNGE's digital MSK therapy platform leverages AI and behavioral support but faces competition, regulatory risks, and heavy reliance on R&D execution. Despite positive non-GAAP operating income and strong liquidity, GAAP losses are inflated by IPO-related stock-based compensation, raising profitability concerns.

SAN FRANCISCO--(BUSINESS WIRE)--Hinge Health, Inc. (NYSE: HNGE) announced today that it will report its financial results for the quarter ended September 30, 2025, after the U.S. markets close on Tuesday, November 4, 2025. Hinge Health will also host an earnings conference call to discuss its results and guidance at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) the same day. The live audio webcast of the earnings conference call will be available on the Hinge Health Investor Relations website.